Loading patent…
AssigneeHoba Therapeutics Aps
InventorsMette Grønborg, Philip Kusk, Nikolaj Blom, Thomas Nordahl Petersen, Teit E. Johansen, Søren Brunak, Lars U. Wahlberg
Estimating the term…
The present invention relates to the field of therapeutic use of proteins, genes and cells. More specifically the invention relates to therapy based on the biological function of a secreted therapeutic protein, NsG33, in particular for the treatment of disorders of the nervous system. NsG33 is a nerve survival and growth factor with antiapoptotic effects on a cell line with neuronal potential and with neuroprotective and/or neurogenesis effects on a neural precursor cell line and on primary striatal cultures. The invention also relates to novel bioactive NsG33 polypeptide fragments and the corresponding encoding DNA sequences.
A method of treating Huntington's disease in a human subject in need thereof comprising providing trophic support to striatal neurons by administering to the subject a therapeutically effective amount of a neurotrophic polypeptide comprising an amino acid sequence:
A method of treating Huntington's disease in a human subject in need thereof comprising providing trophic support to striatal neurons by administering to the striatum of the subject a therapeutically effective amount of a neurotrophic polypeptide comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:
A method of providing trophic support to striatal neurons in a human subject in need thereof, comprising administering to the striatum of the subject a therapeutically effective amount of a neurotrophic polypeptide comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:
Dependencies are inferred from the claim text.